6Ostrowski MJ.An Assessment of the longterm results of controlling the reaccumulation of malignant effusion using intracarity bleomycin.Cancer,1986,57:721
7阴健.中药现代研究与临床应用.北京:学苑出版社,1999.592
8李鼎九.肿瘤热疗学.郑州:河南医科大学出版社,1995.370-372
9李春启,张秀荣.胃癌的化学治疗.北京:中国医药科技出版社,1995.158-159
10Bergman B, Aaronson N K, Ahmedzai S, et al. The EORTC QLQ-LC13:a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials.EORTC Study Group on Quality of Life[J]. Eur J Cancer, 1994, 30A(5):635-642.
3Bookman M A. First - line Chemotherapy in Epithelial Ovar Jan Cancer[j ]. Clin Obstet Gyneeol, 2012, 55(1 ) : 96.
4Zavesky L, Jancarkova N, Kohoutova M. Ovarian cancer: o-rigin and factors involved in carcinogenesis with potential use in diagnosis, treatment and prognosis of the disease[J ]. Neo- plasma, 2011, 58(6): 457.
5Onda T, Yoshikawa H. Neoadjuvant chemotherapy for ad- vanced ovarian cancer : overview of outcomes and unanswered questions[ J ]. Expert Rev Anticancer Ther, 2011, ( 7 ) : 1053.
6Morotti M, Valenzano Menada M, et al. Pemetrexed disodi- um in ovarian cancer treatment [J ]. Expert ()pin lnvestig Drugs, 2012: [Epub ahead of print].
7Ledermarm J A, Stebbing J. Positioning pemetrexed in the treatment of ovarian cancer[J]. Eur J Cancer, 2009, 45(8) : 1330.
8Ogasawara T, Kasamatsu N, Umezawa H, et al. Retrospec tive analysis of pemetrexed plus cisplatin chemotherapy for el derly advanced non- small - cell lung cancer[J]. Gan To Ka gaku Ryoho, 2011, 38(11): 1813.
